Q3 2025 Altimmune Inc Earnings Call Transcript

Nov 6, 2025 / 01:30 PM GMT

Release Date Price: MXN71.8 (-1.64%)

Transcript 10-Q8-K

Key Points

Positve

Altimmune Inc (ALT) reported a significant increase in cash reserves, reaching $211 million, a 60% increase from the start of the year.
The company successfully completed enrollment in the Reclaim phase 2 trial for alcohol use disorder (AUD) ahead of schedule, indicating strong interest and execution capability.
Altimmune Inc (ALT) is preparing for a phase 3 program with a flexible design to adapt to potential regulatory changes, enhancing its strategic positioning.
The company has strengthened its executive team with key appointments, including a new Chief Medical Officer, Chief Commercial Officer, and Chief Legal Officer.
Altimmune Inc (ALT) has received positive feedback from healthcare professionals and payers in Europe, with a high likelihood of prescribing their therapy based on its projected profile.

Negative

The company reported a net loss of $19 million for the third quarter of 2025, although this was an improvement from the previous year.
Research and development expenses were significant, totaling $15 million for the quarter, reflecting ongoing high costs associated with clinical trials.
There is uncertainty regarding the regulatory environment, particularly concerning the potential shift from biopsy readings to non-invasive tests (NITs) for clinical trials.
The competitive landscape for MASH therapies is becoming crowded, with potential new entrants like semaglutide and FGF21 combinations.
Despite progress, the company still faces challenges in proving the long-term efficacy and safety of its therapies, particularly in the context of phase 3 trials.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ALT.OQ - Altimmune Inc
Q3 2025 Altimmune Inc Earnings Call
Nov 06, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning ladies and gentlemen and welcome to the Altimmune 3rd quarter 2025 financial results conference call.

All participants will be in the listen-only mode. Should you need assistance, please signal and conference specialists by pressing the star key, followed by 0.

After today's presentation, there will be an opportunity to ask questions.

To ask a question, you press star and then one on your touchtone phone.

To withdraw your question, you press arar and then to As a reminder, this call is being recorded.

I'll now introduce your host for today's conference call, Lee Roth, President of Burns McClellan Investor Relations Advisor to Altimmune.

Thank you and over to you.

------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.